Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
1(25%)
Results Posted
33%(1 trials)

Phase Distribution

Ph not_applicable
1
25%
Ph phase_1
1
25%
Ph phase_2
1
25%

Phase Distribution

1

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(3)

Detailed Status

Completed3
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (33.3%)
Phase 21 (33.3%)
N/A1 (33.3%)

Trials by Status

recruiting125%
completed375%

Recent Activity

1 active trials
Showing 4 of 4
recruitingphase_1

Pilot Imaging Study of Leukemia

NCT03633955
completed

FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma

NCT01410630
completedphase_2

A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NSCLC

NCT00963807
completednot_applicable

Investigate Role of Metabolic Imaging in Predicting Tumor Response/Outcome After Pancreatic CA Tx

NCT00767273

Clinical Trials (4)

Showing 4 of 4 trials
NCT03633955Phase 1

Pilot Imaging Study of Leukemia

Recruiting
NCT01410630

FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma

Completed
NCT00963807Phase 2

A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NSCLC

Completed
NCT00767273Not Applicable

Investigate Role of Metabolic Imaging in Predicting Tumor Response/Outcome After Pancreatic CA Tx

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4